Do analysts prefer COYA or BYSI?

Coya Therapeutics currently has a consensus price target of $15.33, suggesting a potential upside of 209.76%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Coya Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to COYA or BYSI?

In the previous week, Coya Therapeutics had 2 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for Coya Therapeutics and 3 mentions for BeyondSpring. Coya Therapeutics' average media sentiment score of 0.11 beat BeyondSpring's score of 0.08 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IMDX or BYSI?

Oncocyte presently has a consensus target price of $10.50, suggesting a potential upside of 211.57%. Given Oncocyte's stronger consensus rating and higher probable upside, analysts clearly believe Oncocyte is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncocyte 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IMDX or BYSI more profitable?

BeyondSpring has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Company Net Margins Return on Equity Return on Assets Oncocyte -2,955.63% N/A -107.52% BeyondSpring N/A N/A -28.88%

Does the media prefer IMDX or BYSI?

In the previous week, BeyondSpring had 1 more articles in the media than Oncocyte. MarketBeat recorded 3 mentions for BeyondSpring and 2 mentions for Oncocyte. BeyondSpring's average media sentiment score of 0.08 beat Oncocyte's score of -0.63 indicating that BeyondSpring is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CRBP or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -87.05% -74.22% BeyondSpring N/A N/A -28.88%

Do analysts rate BYSI or ANIX?

Anixa Biosciences has a consensus target price of $8.00, indicating a potential upside of 175.86%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anixa Biosciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is BYSI or ANIX more profitable?

BeyondSpring's return on equity of 0.00% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -28.88% Anixa Biosciences N/A -76.59% -67.80%

Does the media refer more to BYSI or ANIX?

In the previous week, Anixa Biosciences had 2 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for Anixa Biosciences and 3 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.08 beat Anixa Biosciences' score of -0.43 indicating that BeyondSpring is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Anixa Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is BDTX or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% BeyondSpring N/A N/A -28.88%

Does the media prefer BDTX or BYSI?

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than BeyondSpring. MarketBeat recorded 6 mentions for Black Diamond Therapeutics and 3 mentions for BeyondSpring. Black Diamond Therapeutics' average media sentiment score of 0.92 beat BeyondSpring's score of 0.08 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

BeyondSpring (BYSI) Competitors

$0.61 0.00 (-0.56%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.64 +0.03 (+5.35%)

As of 10/9/2026 07:58 PM Eastern

Compare

BYSI vs. COYA, IMDX, CRBP, ANIX, and BDTX

Should you buy BeyondSpring stock or one of its competitors? BeyondSpring's main competitors and comparable companies include Coya Therapeutics (COYA), Oncocyte (IMDX), Corbus Pharmaceuticals (CRBP), Anixa Biosciences (ANIX), and Black Diamond Therapeutics (BDTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BeyondSpring compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Coya Therapeutics had 2 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for Coya Therapeutics and 3 mentions for BeyondSpring. Coya Therapeutics' average media sentiment score of 0.11 beat BeyondSpring's score of 0.08 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeyondSpring has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. BeyondSpring's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
BeyondSpring	N/A	N/A	-28.88%

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BeyondSpring has lower revenue, but higher earnings than Coya Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	14.61	-$21.23M	-$1.07	N/A
BeyondSpring	$1.75M	14.23	-$1.01M	-$0.12	N/A

Coya Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, BeyondSpring has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market.

Coya Therapeutics currently has a consensus price target of $15.33, suggesting a potential upside of 209.76%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Coya Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Coya Therapeutics beats BeyondSpring on 9 of the 16 factors compared between the two stocks.

How does BeyondSpring compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Oncocyte presently has a consensus target price of $10.50, suggesting a potential upside of 211.57%. Given Oncocyte's stronger consensus rating and higher probable upside, analysts clearly believe Oncocyte is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring has lower revenue, but higher earnings than Oncocyte. BeyondSpring is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	27.23	-$50.22M	-$1.49	N/A
BeyondSpring	$1.75M	14.23	-$1.01M	-$0.12	N/A

In the previous week, BeyondSpring had 1 more articles in the media than Oncocyte. MarketBeat recorded 3 mentions for BeyondSpring and 2 mentions for Oncocyte. BeyondSpring's average media sentiment score of 0.08 beat Oncocyte's score of -0.63 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

55.4% of Oncocyte shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 2.2% of Oncocyte shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oncocyte has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, BeyondSpring has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market.

BeyondSpring has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
BeyondSpring	N/A	N/A	-28.88%

Summary

Oncocyte beats BeyondSpring on 8 of the 15 factors compared between the two stocks.

How does BeyondSpring compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BeyondSpring's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%
BeyondSpring	N/A	N/A	-28.88%

Corbus Pharmaceuticals currently has a consensus target price of $41.00, indicating a potential upside of 662.08%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Corbus Pharmaceuticals is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Corbus Pharmaceuticals has a beta of 2.63, meaning that its stock price is 163% more volatile than the broader market. Comparatively, BeyondSpring has a beta of -0.21, meaning that its stock price is 121% less volatile than the broader market.

BeyondSpring has higher revenue and earnings than Corbus Pharmaceuticals. BeyondSpring is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A
BeyondSpring	$1.75M	14.23	-$1.01M	-$0.12	N/A

In the previous week, BeyondSpring had 2 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 3 mentions for BeyondSpring and 1 mentions for Corbus Pharmaceuticals. BeyondSpring's average media sentiment score of 0.08 beat Corbus Pharmaceuticals' score of 0.00 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Neutral
BeyondSpring	Neutral

Summary

BeyondSpring beats Corbus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does BeyondSpring compare to Anixa Biosciences?

BeyondSpring (NASDAQ:BYSI) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BeyondSpring has a beta of -0.21, indicating that its stock price is 121% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

In the previous week, Anixa Biosciences had 2 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for Anixa Biosciences and 3 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.08 beat Anixa Biosciences' score of -0.43 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anixa Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Anixa Biosciences has a consensus target price of $8.00, indicating a potential upside of 175.86%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

BeyondSpring's return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-28.88%
Anixa Biosciences	N/A	-76.59%	-67.80%

BeyondSpring has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than BeyondSpring, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	14.23	-$1.01M	-$0.12	N/A
Anixa Biosciences	$210K	480.02	-$10.93M	-$0.32	N/A

Summary

BeyondSpring beats Anixa Biosciences on 9 of the 15 factors compared between the two stocks.

How does BeyondSpring compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than BeyondSpring. MarketBeat recorded 6 mentions for Black Diamond Therapeutics and 3 mentions for BeyondSpring. Black Diamond Therapeutics' average media sentiment score of 0.92 beat BeyondSpring's score of 0.08 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Black Diamond Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 460.11%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Black Diamond Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Black Diamond Therapeutics has higher revenue and earnings than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.50	$22.37M	-$0.75	N/A
BeyondSpring	$1.75M	14.23	-$1.01M	-$0.12	N/A

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BeyondSpring's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
BeyondSpring	N/A	N/A	-28.88%

Black Diamond Therapeutics has a beta of 3.32, indicating that its stock price is 232% more volatile than the broader market. Comparatively, BeyondSpring has a beta of -0.21, indicating that its stock price is 121% less volatile than the broader market.

Summary

Black Diamond Therapeutics beats BeyondSpring on 11 of the 15 factors compared between the two stocks.

Get BeyondSpring News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BYSI vs. The Competition

Export

Metric	BeyondSpring	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.90M	$3.93B	$7.26B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-5.05	13.55	274.99	26.14
Price / Sales	14.23	1,209.42	582.85	87.95
Price / Cash	5.33	119.49	76.96	53.71
Price / Book	-1.03	17.17	11.22	6.33
Net Income	-$1.01M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-23.08%	-1.34%	-0.89%	-1.40%
1 Month Performance	-21.02%	-8.45%	-4.42%	-3.47%
1 Year Performance	-65.20%	14.02%	7.03%	1.18%

BeyondSpring Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BYSI BeyondSpring	0.2271 of 5 stars	$0.61 -0.6%	N/A	-66.5%	$24.90M	$1.75M	N/A	44	Analyst Upgrade Gap Down
COYA Coya Therapeutics	2.3347 of 5 stars	$4.91 +1.2%	$15.33 +212.3%	-21.1%	$113.77M	$7.95M	N/A	8
IMDX Oncocyte	3.4726 of 5 stars	$3.46 +2.4%	$10.50 +203.5%	N/A	$110.61M	$4.05M	N/A	58
CRBP Corbus Pharmaceuticals	3.5248 of 5 stars	$5.49 -5.0%	$41.00 +646.8%	-65.7%	$107.92M	N/A	N/A	36
ANIX Anixa Biosciences	3.4255 of 5 stars	$2.95 -2.3%	$8.00 +171.2%	-41.1%	$104.99M	$210K	N/A	4	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BYSI) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeyondSpring (BYSI) Competitors

BYSI vs. COYA, IMDX, CRBP, ANIX, and BDTX

How does BeyondSpring compare to Coya Therapeutics?

Summary

How does BeyondSpring compare to Oncocyte?

Summary

How does BeyondSpring compare to Corbus Pharmaceuticals?

Summary

How does BeyondSpring compare to Anixa Biosciences?

Summary

How does BeyondSpring compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeyondSpring (BYSI) Competitors

BYSI vs. COYA, IMDX, CRBP, ANIX, and BDTX

How does BeyondSpring compare to Coya Therapeutics?

Does the media refer more to COYA or BYSI?

Is COYA or BYSI more profitable?

Do institutionals & insiders have more ownership in COYA or BYSI?

Which has higher valuation & earnings, COYA or BYSI?

Which has more volatility & risk, COYA or BYSI?

Do analysts prefer COYA or BYSI?

Summary

How does BeyondSpring compare to Oncocyte?

Do analysts rate IMDX or BYSI?

Which has higher valuation & earnings, IMDX or BYSI?

Does the media prefer IMDX or BYSI?

Do institutionals & insiders have more ownership in IMDX or BYSI?

Which has more volatility & risk, IMDX or BYSI?

Is IMDX or BYSI more profitable?

Summary

How does BeyondSpring compare to Corbus Pharmaceuticals?

Do insiders & institutionals hold more shares of CRBP or BYSI?

Is CRBP or BYSI more profitable?

Do analysts recommend CRBP or BYSI?

Which has more risk & volatility, CRBP or BYSI?

Which has better valuation & earnings, CRBP or BYSI?

Does the media refer more to CRBP or BYSI?

Summary

How does BeyondSpring compare to Anixa Biosciences?

Do institutionals & insiders believe in BYSI or ANIX?

Which has more risk & volatility, BYSI or ANIX?

Does the media refer more to BYSI or ANIX?

Do analysts rate BYSI or ANIX?

Is BYSI or ANIX more profitable?

Which has higher earnings and valuation, BYSI or ANIX?

Summary

How does BeyondSpring compare to Black Diamond Therapeutics?

Does the media prefer BDTX or BYSI?

Do analysts prefer BDTX or BYSI?

Which has better earnings & valuation, BDTX or BYSI?

Do institutionals and insiders hold more shares of BDTX or BYSI?

Is BDTX or BYSI more profitable?

Which has more risk & volatility, BDTX or BYSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools